Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
SARC037: a Phase I/II Study to Evaluate the Safety of Trabectedin in Combination with Irinotecan in Ewing Sarcoma Patients
- Conditions
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 48
- Registration Number
- NCT04067115
- Locations
- 🇺🇸
Boston Children's Hospital / Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸National Cancer Institute, Bethesda, Maryland, United States
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 120
- Registration Number
- NCT04034173
- Locations
- 🇩🇪
Ludwigs Maximialians University, Munich, Germany
FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC
- Conditions
- Interventions
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 109
- Registration Number
- NCT04034459
- Locations
- 🇩🇪
Klinikum der Universitaet Muenchen, Munich, Germany
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1147
- Registration Number
- NCT04008030
- Locations
- 🇩🇪
Local Institution - 0117, Hamburg, Germany
🇩🇪Local Institution - 0008, Hannover, Germany
🇩🇪Local Institution - 0009, Heidelberg, Germany
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT03977233
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT03970252
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
- First Posted Date
- 2019-05-24
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 112
- Registration Number
- NCT03963193
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
- Conditions
- Interventions
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 123
- Registration Number
- NCT03933449
- Locations
- 🇨🇳
Wuhan Tongji Hospital ( Site 0724), Wuhan, Hubei, China
🇨🇳Jiangsu Cancer Hospital (Site 0704), Nanjing, Jiangsu, China
🇨🇳The First Affiliated Hospital of Anhui Medical University ( Site 0707), Hefei, Anhui, China
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT03879798
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Commack, Commack, New York, United States
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Toray Industries, Inc
- Target Recruit Count
- 187
- Registration Number
- NCT03872947
- Locations
- 🇺🇸
HOAG Memorial Hospital Presbyterian, Newport, California, United States
🇺🇸Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Northwest Cancer Specialists, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.